Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Geron Corporation
< Previous
1
2
3
4
Next >
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
April 25, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Participate at Upcoming Investor Conferences in April
April 03, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
March 19, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
March 14, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 22, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
February 14, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
January 12, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
December 11, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
December 06, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
December 04, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
November 28, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Participate at Upcoming Investor Conferences in November
November 07, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
November 02, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
November 02, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023
October 26, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 19, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
September 29, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
September 11, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
September 07, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Participate in the Baird 2023 Global Healthcare Conference
September 05, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
August 22, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
August 21, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results
August 03, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
July 27, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.